NCT07803250 was first posted on 3 September 2026. The public record names the University of Arkansas as sponsor and describes a phase 1 investigation of BPC-157 after rotator-cuff repair. In the snapshot reviewed 29 October, it was not yet recruiting, with an estimated 1 January 2027 start and no posted results module.
Those are the submitter’s registry statements. We have not independently confirmed enrollment arrangements with the institution or inspected an ethics approval, FDA filing or protocol outside the registry. A sponsor field is not independent institutional confirmation.
Two contradictions worth preserving
The structured enrollment field estimates 30 participants. The brief summary says twenty. Choosing the larger number for a market-sizing chart or the smaller number to criticize statistical power would silently resolve a conflict the record itself has not resolved.
The brief summary describes a saline placebo, and the sham-arm description also says participants receive saline injections. The linked intervention, however, is labeled “Sham (No Treatment).” The distinction matters for interpreting masking and expectations. We retain both descriptions rather than declare the study definitively placebo-controlled or definitively unblinded on the basis of one field.
An endpoint is not an outcome
The registered primary measure is shoulder strength, assessed using a handheld dynamometer at specified follow-up points. The summary also mentions MRI, patient-reported measures, range of motion and blood biomarkers. These are planned assessments, not observed improvements. The record supplies no result from which to estimate a treatment effect or an adverse-event rate.
The summary’s claim that BPC-157 has not been studied in formal human clinical trials is submitter language, not a conclusion adopted by this publication. Our separate published-evidence review and the registry’s older and commercial-product records require their own interpretation. A planned university study does not prove that all earlier reports are nonexistent, nor that earlier reports establish effectiveness.
What a practice can accurately communicate
A cautious statement is that a registry record describes a planned early-phase study after a particular surgery; it does not yet report results and contains unresolved design fields. That is different from saying a university has proved BPC-157 heals tendons. It does not support extrapolation to nonsurgical injuries, general wellness, a different formulation or a research-seller product.
Evidence record
Event date: 2026-09-03. Source review: 2026-10-29. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.
- ClinicalTrials.gov NCT07803250 · original record and history ↗
- ClinicalTrials.gov · government review and sponsor responsibilities ↗
Revision history
29 October 2026: authored from the public registry snapshot and separate screening ledger. No independent sponsor contact, regulatory-file verification or full-paper efficacy review performed. Report a proposed correction through Contact us; do not include patient data.